Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Erasmus Medical Center |
---|---|
Information provided by: | Erasmus Medical Center |
ClinicalTrials.gov Identifier: | NCT00642720 |
Study Synopsis Study Title: Double blind, single centre, cross-over study on the effects of weekly subcutaneous administration of 40 mg pegvisomant or placebo on quality of life and insulin sensitivity in acromegalic patients with normal serum IGF-I concentrations during long-term treatment with long-acting somatostatin analogs
Study Objectives:
Study Population: Acromegalic patients, who have normalized their serum IGF-I levels down to the upper 25 centiles of normality during long-term treatment with monthly injections of a long-acting somatostatin analogue Number of Subjects: 20
Procedures:
Hypothesis:
Condition | Intervention | Phase |
---|---|---|
Quality of Life Acromegaly |
Drug: Pegvisomant |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Crossover Assignment, Efficacy Study |
Official Title: | The Effects of Weekly Administration of 40 mg Pegvisomant or Placebo on Quality of Life and Insulin Sensitivity in Acromegalic Patients With Normal IGF-I Concentrations During Long-Term Treatment With Long-Acting Somatostatin Analogs |
Enrollment: | 20 |
Study Start Date: | October 2006 |
Study Completion Date: | July 2007 |
Primary Completion Date: | July 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
pegvisomant-placebo
patients in this arm received(as addition)for the first 8 weeks Pegvisomant and the later for 8 weeks Placebo. This was divided by a 4 weeks wash-out period.
|
Drug: Pegvisomant
if the addition of 40 mg pegvisomant weekly will improve the quality of life of acromegaly patients compared to placebo weekly
|
placebo-pegvisomant
Patient received for the first 8 weeks Pegvisomant and after a wash out period of 4 weeks the received 8 of placebo treatment
|
Drug: Pegvisomant
if the addition of 40 mg pegvisomant weekly will improve the quality of life of acromegaly patients compared to placebo weekly
|
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Erasmus Medical center ( Aart-Jan van der Lely ) |
Study ID Numbers: | *P05.1649L, *P05.1649L CCMO |
Study First Received: | March 21, 2008 |
Last Updated: | March 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00642720 History of Changes |
Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Bone Diseases, Endocrine Hypothalamic Diseases Pituitary Diseases Central Nervous System Diseases Endocrine System Diseases Quality of Life Brain Diseases |
Bone Diseases Insulin Somatostatin Musculoskeletal Diseases Endocrinopathy Acromegaly |
Bone Diseases, Endocrine Hypothalamic Diseases Hyperpituitarism Pituitary Diseases Musculoskeletal Diseases Nervous System Diseases |
Endocrine System Diseases Central Nervous System Diseases Brain Diseases Bone Diseases Acromegaly |